Title:
ANTITUMOR AGENT
Document Type and Number:
WIPO Patent Application WO/2022/244876
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a new antitumor agent. Specifically, the present invention uses, as an antitumor agent, T-cells expressing a T-cell receptor including a peptide represented by SEQ ID NO: 1 and a peptide represented by SEQ ID NO: 2, in a T-cell receptor gene introduction T-cell therapy.
Inventors:
MATSUSHITA MAIKO (JP)
HATTORI YUTAKA (JP)
KAWAKAMI YUTAKA (JP)
HATTORI YUTAKA (JP)
KAWAKAMI YUTAKA (JP)
Application Number:
PCT/JP2022/020990
Publication Date:
November 24, 2022
Filing Date:
May 20, 2022
Export Citation:
Assignee:
UNIV KEIO (JP)
International Classes:
C12N15/12; A61K31/7088; A61K35/17; A61K38/16; A61K45/00; A61P13/08; A61P35/00; A61P43/00; C07K14/725; C12N5/0783; C12N5/10; C12N15/85; C12Q1/02; G01N33/53
Domestic Patent References:
| WO2020082130A1 | 2020-04-30 | |||
| WO2020172332A1 | 2020-08-27 |
Foreign References:
| JP2013256454A | 2013-12-26 |
Other References:
MATSUSHITA, M. ET AL.: "Abstract B73: A novel candidate for immunologic target in treatment of multiple myeloma", CANCER IMMUNOLOGY RESEARCH JUL 2014, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 8, no. 3, US , pages B73 - B73, XP009541180, ISSN: 2326-6074, Retrieved from the Internet [retrieved on 20220627], DOI: 10.1158/2326-6074.TUMIMM19-B73
Attorney, Agent or Firm:
ISSHIKI & CO. (JP)
Download PDF: